Psychiatry Medical News about Alzheimer's disease ADAS-cog

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease
International Journal of Geriatric Psychiatry, 06/30/09

A 4-point ADAS-cog change at 6 months is clinically meaningful for groups. Substantial individual misclassification between the ADAS-cog and clinical measures suggests no inherent meaning to a 4-point ADAS-cog change for a given patient.

Methods

Secondary analysis of the video imaging synthesis of treating Alzheimer's disease (VISTA) study: a 4-month, multi-centre, parallel-group, double-blind, placebo-controlled, trial of galantamine in 130 mild-moderate Alzheimer's disease patients (4-month open-label follow-up).
ADAS-cog responses at 6 months were compared with outcomes on three clinical measures: clinician's interview based impression of change-plus caregiver input (CIBIC+), patient/carer-goal attainment scaling (PGAS) and clinician-GAS (CGAS).

Results

Thirty-seven of 99 patients improved by 4 points on the ADAS-cog at 6 months, and 16/99 showed 4-point worsening.
ADAS-cog change scores correlated notionally to modestly with changes on the CGAS (r = -0.31), the PGAS (r = -0.29) and the CIBIC+ (r = 0.31).
As a group, patients with ADAS-cog improvement were significantly more likely to improve on the clinical measures; those who worsened showed non-significant clinical decline.
Individually, about half were misclassified in relation to each clinical measure; often when the ADAS-Cog detected no change, clinically meaningful effects could be detected. Even so, no ADAS-Cog cut-point optimally classified patients' clinical responses.

<< Previous
Binge drinking and depressive symptoms: a 5-year population-based...

Next >>
Cancer mortality in patients with schizophrenia